Zanubrutinib plus pemetrexed for recurrent brain lymphomas
Treatments studied
Part of Cancer clinical trials.
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed CNS lymphoma (brain/spinal lymphoma) or an ocular lymphoma that also has measurable brain tumor
- Your scans show no lymphoma in the rest of your body (chest/abdomen/pelvis)
- Your disease has returned or did not respond to earlier chemotherapy and/or radiation, or you could not tolerate it
- You are well enough for treatment (Karnofsky score at least 30%, or 50% if age 60+)
- Your blood counts and organs (kidney/liver) meet specific lab thresholds
- You can follow study steps, sign consent, and are expected to live at least 2 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking the drug tirabrutinib (a pill) can help keep primary CNS lymphoma from coming back after successful initial chemotherapy. It compares the drug to a placebo (a dummy pill).
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
This trial tests a combination of targeted therapy (zanubrutinib) plus a standard chemo-immunotherapy regimen (pola-R-CHP) and high-dose methotrexate for people whose large B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this approach can effectively treat lymphoma in both the body and the central nervous system.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.